|Ms. Jennifer L. Good||Co-Founder, CEO, Pres, Principal Financial Officer & Director||662.64k||N/A||1965|
|Dr. Thomas R. Sciascia||Co-Founder & Chief Medical Officer||476.25k||N/A||1953|
|Mr. Christopher Galletta||Controller & Chief Accounting Officer||N/A||N/A||1978|
|Dr. Amale Hawi||Sr. VP of CMC||N/A||N/A||1954|
|Mr. Frank P. Muscolo||Exec. Officer||N/A||N/A||1957|
|Dr. William P. Forbes Pharm.D., Pharm. D.||Chief Devel. Officer||N/A||N/A||1962|
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.